drugset / Trial / NCT03722108
Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
RandomizedParallel-groupOpen-labelTreatment
Summary
Trial evaluating the efficacy of regorafenib combined with irinotecan compared to irinotecan alone in second-line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.
Timeline
- Start
- 2019-02-07
- Primary completion
- 2022-05-19
- Completion
- 2022-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Irinotecan | Small molecule | 180 mg/m2 | — |
| Subject | Regorafenib | Small molecule | 160 mg | — |